Semaglutide

Semaglutide is a synthetic research peptide belonging to the glucagon-like peptide-1 (GLP-1) receptor agonist class. It is a modified peptide consisting of 31 amino acids, developed to activate the GLP-1 receptor and support scientific investigation into incretin signalling, glucose regulation and metabolic pathways.

In laboratory research, Semaglutide is studied for its receptor-binding characteristics, prolonged molecular activity and role in GLP-1 signalling. GreenLabs AU supplies Semaglutide as a freeze-dried (lyophilised) powder in sealed vials, strictly for in-vitro laboratory research only.

Key highlights

• Compound: Semaglutide, a synthetic GLP-1 receptor agonist research peptide.
• Mechanism: Selectively activates the GLP-1 receptor, a target involved in glucose-dependent insulin signalling and metabolic regulation.
• Form: White to off-white freeze-dried (lyophilised) powder in a sealed vial.
• Molecular structure: Modified 31-amino-acid peptide designed for prolonged activity.
• Purity: Refer to the applicable batch Certificate of Analysis (CoA) for verified results.
• Sizes: 10mg
• Shipping: Dispatch generally within 24 hours on business days; free shipping on orders over $150 AUD

What is Semaglutide? A plain explanation

Semaglutide is a synthetic peptide designed to mimic certain biological actions of glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone involved in glucose regulation and metabolic signalling.

An agonist is a molecule that binds to a receptor and activates it. Semaglutide acts as a GLP-1 receptor agonist, meaning it interacts with the GLP-1 receptor and initiates downstream cellular signalling.

Unlike dual-acting compounds such as Tirzepatide, which activates both GIP and GLP-1 receptors, Semaglutide primarily targets the GLP-1 receptor.

This selectivity makes Semaglutide a useful reference compound in laboratory studies examining GLP-1 receptor activation, receptor signalling and the biological differences between single-receptor and multi-receptor agonists.

How Semaglutide works at the receptor level

Semaglutide is structurally related to native GLP-1 but incorporates modifications that extend its biological activity.

Natural GLP-1 is rapidly broken down by enzymes, including dipeptidyl peptidase-4 (DPP-4). Semaglutide contains structural modifications that increase resistance to enzymatic degradation and promote albumin binding, contributing to its prolonged activity.

At the cellular level, Semaglutide binds to the GLP-1 receptor, a G protein-coupled receptor (GPCR). Receptor activation stimulates intracellular signalling pathways, including cyclic adenosine monophosphate (cAMP) production.

These pathways are relevant to scientific investigations into glucose-dependent insulin secretion, glucagon signalling and metabolic regulation.

Researchers may compare Semaglutide with other incretin-related compounds, including Tirzepatide and Retatrutide, to examine how different receptor activation profiles influence cellular responses.

Semaglutide in laboratory research

Semaglutide is widely studied in the context of GLP-1 receptor biology and incretin-related signalling.

Research applications include:

• GLP-1 receptor activation: Investigating how receptor binding initiates downstream cellular responses.
• Incretin signalling: Studying pathways associated with glucose-dependent insulin and glucagon regulation.
• Receptor selectivity: Comparing single-receptor GLP-1 agonists with dual- and triple-receptor compounds.
• Peptide stability: Examining how molecular modifications influence degradation resistance and binding characteristics.
• Metabolic research: Investigating cellular pathways associated with glucose and energy regulation.

Within laboratory research, Semaglutide may be compared with Tirzepatide, a dual GIP/GLP-1 receptor agonist, or Retatrutide, a triple GIP/GLP-1/glucagon receptor agonist.

These comparisons help researchers investigate differences in receptor selectivity and signalling mechanisms.

Purity and third-party testing (Certificate of Analysis)

GreenLabs AU provides third-party testing documentation for applicable Semaglutide batches.

A Certificate of Analysis (CoA) may include analytical information such as peptide identity, purity and the testing methods used.

High-performance liquid chromatography (HPLC) is commonly used to evaluate peptide purity by separating components within a sample. Additional analytical methods may be used to assess molecular identity.

Researchers should review the Certificate of Analysis corresponding to their product batch rather than relying on a general purity claim.

Available testing documentation can be accessed through our certificates page.

Semaglutide in Australia and New Zealand: sizes, shipping and bulk

GreenLabs AU supplies Semaglutide for laboratory research in sealed, lyophilised vials.

• Dispatch: Generally within 24 hours on business days
• Delivery: Typically 2–4 business days for most Australian destinations
• Western Australia: Allow approximately 4–6 business days
• Free shipping: On orders over $150 AUD

For larger laboratory projects, available bulk configurations may offer a lower price per vial compared with individual purchases.

All products are supplied strictly for legitimate laboratory research and are not intended for human or animal administration.

Storage and handling of Semaglutide

Semaglutide is supplied in lyophilised form to support stability during storage and laboratory handling.

• Store sealed vials according to the manufacturer’s documented storage conditions.
• Protect research samples from excessive heat, moisture and direct sunlight.
• Use appropriate laboratory procedures when preparing samples for analytical testing.
• Follow validated laboratory protocols and the applicable product documentation for solution preparation and storage.
• Avoid unnecessary temperature fluctuations and repeated freeze-thaw cycles where stability has not been established.

Storage conditions for prepared solutions may differ from those for lyophilised material and should be established using validated stability information.

Semaglutide specifications

Semaglutide FAQs

What is Semaglutide?

Semaglutide is a synthetic GLP-1 receptor agonist consisting of 31 amino acids. It is structurally modified to provide prolonged activity compared with naturally occurring GLP-1 and is studied for its receptor-binding and signalling properties.

Is Semaglutide a peptide or a steroid?

Semaglutide is a peptide, not a steroid. It consists of a modified amino-acid chain and belongs to the GLP-1 receptor agonist class. Steroids have a different chemical structure and operate through different biological mechanisms.

Is Semaglutide a GLP-1 or GIP agonist?

Semaglutide is a GLP-1 receptor agonist. Unlike Tirzepatide, which activates both GIP and GLP-1 receptors, Semaglutide is designed to target the GLP-1 receptor.

What is the difference between Semaglutide and Tirzepatide?

The main difference is their receptor activity. Semaglutide acts as a GLP-1 receptor agonist, whereas Tirzepatide activates both GLP-1 and GIP receptors. These differences make them useful comparison compounds in research investigating incretin receptor signalling.

How pure is GreenLabs AU Semaglutide, and can I view a CoA?

Purity and identity information should be confirmed using the Certificate of Analysis for the applicable batch. Available third-party testing documentation can be found on the GreenLabs AU certificates page.

How should Semaglutide be stored?

Sealed Semaglutide research vials should be stored according to the manufacturer’s specifications. Prepared solutions may have different stability requirements and should be handled using validated laboratory procedures.

What does the milligram number mean?

The milligram (mg) number indicates the nominal quantity of Semaglutide contained in a vial. It describes the supplied research material and is not a recommended administration dose.

Is Semaglutide approved for medical use?

Semaglutide is an active ingredient in certain approved prescription medicines, including products authorised by regulatory agencies such as Australia’s TGA and the US FDA.

However, GreenLabs AU’s research-grade Semaglutide is not an approved medicine and must not be represented as equivalent to an authorised pharmaceutical product. It is supplied exclusively for laboratory research and is not intended for human or animal administration.

Disclaimer: GreenLabs AU Semaglutide is supplied strictly for legitimate in-vitro laboratory research. It is not an approved pharmaceutical product, supplement or cosmetic, and is not intended for human or animal use. Purchasers are responsible for complying with applicable laws, regulatory requirements and laboratory safety procedures.